Pharmaceutical

Capstan secures $175m Series B funds for CAR-T therapy

Capstan Therapeutics has secured $175m Series B financing to advance its lead in vivo CAR-T candidate, CPTX2309, for autoimmune disorders.

Mar 22, 2024 - 00:00
Capstan secures $175m Series B funds for CAR-T therapy
Capstan Therapeutics has secured $175m Series B financing to advance its lead in vivo CAR-T candidate, CPTX2309, for autoimmune disorders.
Read the original article

Tags:

Previous Article

Bionomics to advance non-SSRI PTSD candidate to Phase III

Next Article

Delivery and manufacturing hurdles remain in the cell and gene therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ReAlta secures FDA orphan drug and fast track designations for GvHD therapy

ReAlta secures FDA orphan drug and fast track designati...

Aug 21, 2024

Biogen’s higher Spinraza dose shows better efficacy in Phase II/III trial 

Biogen’s higher Spinraza dose shows better efficacy in ...

Sep 8, 2024

FDA accepts Astellas’ sNDA for CRESEMBA to treat fungal infections

FDA accepts Astellas’ sNDA for CRESEMBA to treat fungal...

Aug 12, 2023